Individual quality assessment of autografting by probability evaluation: A model estimated by analysis of graft-related end points in 204 patients with malignancies

Bone Marrow Transplantation

Volumn 31, Issue 6, 2003, Pages 453-458

  Baech, J ^b   Roer, O ^a   Johnsen, H E ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Autografts; CD34; Quality assessment

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CD34 ANTIGEN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; AUTOGRAFT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER REGRESSION; CELL COUNT; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUALITY CONTROL; SCANDINAVIA; TESTIS CANCER; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; BREAST NEOPLASMS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LEUKOCYTES; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIPLE MYELOMA; NEOPLASMS; PROBABILITY; PROGNOSIS; QUALITY ASSURANCE, HEALTH CARE; TESTICULAR NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0012400661     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703828     Document Type: Article

References (14)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97 [see comments].
2. Burnett AK, Goldstone AH, Stevens RM et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-708.
3. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNL1 randomised trial. Lancet 1993; 341: 1051-1054.
4. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
5. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
6. Hjorth M, Holmberg E, Rodjer S et al. Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades Nordic Myeloma Study Group (NMSG). Eur J Haematol 1999; 62: 271-277.
7. Johnsen HE. Report from a Nordic workshop on CD34+ cell analysis: technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories. J Hematother 1995; 4: 21-28.
8. Johnsen HE, Knudsen LM. Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCL-G). J Hematother 1996; 5: 237-245.
9. Johnsen HE, Baech J, Nicolaisen K et al. Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: report from the third workshop. J Hematother 1999; 8: 15-28.
10. Serke S, Johnsen HE. A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts. Bone Marrow Transplant 2001; 27: 463-470.
11. Baech J, Johnsen HE. Technical aspects and clinical impact of hematopoietic progenitor subset quantification. Stem Cells 2000; 18: 76-86.
12. Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13: 1328-1335.
13. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
14. Hartmann O, Le Corroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs A randomized, controlled trial. Ann Intern Med 1997; 126: 600-607.